⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL532650 | 0.95 | — | — | |
| SCHEMBL8603 | 0.94 | — | — | |
| SCHEMBL19439558 | 0.89 | — | — | |
| SCHEMBL9184129 | 0.60 | — | — | |
| SCHEMBL1275267 | 0.59 | — | — | |
| SCHEMBL8765613 | 0.56 | — | — | |
| SCHEMBL1305096 | 0.56 | — | — | |
| SCHEMBL735951 | 0.54 | — | — | |
| SCHEMBL9301124 | 0.53 | — | — | |
| SCHEMBL4135414 | 0.50 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2415776-B1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | NOVARTIS AG (CH) | 2016-05-25 | — | — | EP | disclosed |
| US-9290533-B2 | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B | NOVARTIS AG (CH) | 2016-03-22 | — | — | US | disclosed |
| EP-1572095-B1 | BETA-L-2'-DEOXYNUCLEOSIDES FOR USE IN THE TREATMENT OF RESISTANT HBV STRAINS | NOVARTIS AG (CH) | 2015-06-10 | — | — | EP | disclosed |
| EP-1431304-B1 | Beta - L-2'-Deoxy-Nucleosides for the treatment of Hepatitis B | NOVARTIS AG (CH) | 2014-12-03 | — | — | EP | disclosed |
| US-20130324491-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | IDENIX PHARMACEUTICALS, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| US-20120264707-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | IDENIX PHARMACEUTICALS, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-8158606-B2 | β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies | NOVARTIS, AG (CH) | 2012-04-17 | — | — | US | disclosed |
| EP-2415776-A1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | IDENIX Pharmaceuticals, Inc. (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20110257120-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | IDENIX PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110195922-A9 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | IDENIX PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | US | disclosed |
| US-6407077-B1 | ADMINISTERING B-L-(-2*-AZIDO)-2*,3*-DIDEOXY-5-FLUOROCYTIDINE DERIVATIVE; ACQUIRED IMMUNE DEFICIENCY SYNDROMOE (AIDS) TREATMENT | EMORY UNIVERSITY | 2002-06-18 | — | — | US | disclosed |
| US-6395716-B1 | Antivirals such as telbivudine | NOVIRIO PHARMACEUTICALS LIMITED (KY) | 2002-05-28 | — | — | US | disclosed |
| US-20020035085-A1 | Administering a 2'-deoxy-beta-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof | NOVARTIS AG (CH) | 2002-03-21 | — | — | US | disclosed |
| WO-2001091737-A2 | METHODS FOR TREATING HEPATITIS DELTA VIRUS INFECTION WITH BETA-L-2' DEOXY-NUCLEOSIDES | IDENIX (CAYMAN) LIMITED (KY) | 2001-12-06 | — | — | WO | disclosed |
| EP-1124839-A2 | NUCLEOSIDES WITH ANTI-HEPATITIS B VIRUS ACTIVITY | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2001-08-22 | — | — | EP | disclosed |
| EP-1124565-A1 | AZIDO DERIVATIVES OF BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HIV INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2001-08-22 | — | — | EP | disclosed |
| EP-1104436-A2 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B VIRUS | Idenix (Cayman) Limited (KY) | 2001-06-06 | — | — | EP | disclosed |
| WO-2000026225-A2 | NUCLEOSIDES WITH ANTI-HEPATITIS B VIRUS ACTIVITY | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2000-05-11 | — | — | WO | disclosed |
| WO-2000025799-A1 | β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HIV INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2000-05-11 | — | — | WO | disclosed |
| WO-2000009531-A2 | β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | NOVIRIO PHARMACEUTICALS LIMITED (KY) | 2000-02-24 | — | — | WO | disclosed |